SUE WANG is a litigation partner who represents clients across the life sciences industry in high-stakes patent litigation, with a particular emphasis on biologics, cell-based therapies, and related biotechnology. An experienced litigator and trial lawyer, she has helped clients prevail in precedent-setting disputes involving biologics patents against both biosimilars and competitors.
Outside of the courtroom, Sue leverages her litigation experience to counsel clients on patent- and technology-related matters, including patent analysis for technology acquisitions, freedom-to-operate analysis for pipeline products, and strategic planning for future litigation.
Sue’s recent experience has involved technologies related to: gene editing; RNA interference; antibody therapeutics; protein manufacturing processes; cancer immunotherapy; and T-cell therapies.
Representative litigation matters include:
- Representing biopharmaceutical company in Hatch-Waxman litigation involving psoriasis drug in the District of New Jersey and on appeal to the Federal Circuit.
- Represented biopharmaceutical company in patent litigations involving biosimilars to the company’s blockbuster biologic. As part of trial team, helped secure ruling upholding patent validity following a two-week bench trial in the District of New Jersey. As part of appellate team, helped secure affirmance at the Federal Circuit.
- Represented pharmaceutical company in multiple patent suits involving Factor VIII products. As part of trial team, helped secure a jury victory for the patent owner that resulted in one of the highest biotech verdicts in the District of Delaware. As part of appellate team, helped secure affirmance from the Federal Circuit on all issues. Cases settled favorably.
- Representing multiple software developers in the Northern District of California in patent infringement lawsuits brought by non-practicing entity.
- Represented biopharmaceutical company in first-of-its-kind declaratory judgment patent litigation under the Biologics Price Competition and Innovation Act (BPCIA), successfully securing dismissal for lack of an Article III case or controversy.
Sue also maintains an active pro bono practice, representing individual and institutional clients on immigration-related issues such as asylum, challenges to detention and enforcement policy, and Freedom of Information Act (FOIA) requests.
Sue clerked for Judge Beth Labson Freeman in the Northern District of California from 2014-2015. She earned her J.D. from Stanford Law School, where she was a board member for the Stanford Technology Law Review. She received her B.A., with general honors, in biological sciences and political science from the University of Chicago.